Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
LENZ Therapeutics, Inc. (LENZ) had Return on Tangible Equity of -28.88% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$19.09M |
|
$-82.13M |
|
$0.42M |
|
$18.67M |
|
$110.23M |
|
$-91.14M |
|
$9.51M |
|
$-81.62M |
|
$-81.62M |
|
$-82.13M |
|
$-82.13M |
|
$-82.13M |
|
$-82.13M |
|
$-91.14M |
|
$-90.85M |
|
28.81M |
|
28.81M |
|
$-2.85 |
|
$-2.85 |
|
| Balance Sheet Financials | |
$301.41M |
|
$1.19M |
|
$4.46M |
|
$305.88M |
|
$21.19M |
|
-- |
|
$0.35M |
|
$21.54M |
|
$284.34M |
|
$284.34M |
|
$284.34M |
|
31.34M |
|
| Cash Flow Statement Financials | |
$-69.17M |
|
$-75.67M |
|
$149.75M |
|
$20.27M |
|
$25.18M |
|
$4.91M |
|
$12.55M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.23 |
|
-- |
|
-- |
|
-- |
|
-- |
|
97.81% |
|
-477.46% |
|
-477.46% |
|
-475.96% |
|
-427.62% |
|
-430.25% |
|
$-70.00M |
|
-- |
|
-- |
|
-- |
|
0.06 |
|
0.14 |
|
58.02 |
|
6.29 |
|
-28.88% |
|
|
Return on Tangible Equity |
-28.88% |
-26.85% |
|
-28.88% |
|
$9.07 |
|
$-2.43 |
|
$-2.40 |
|